Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Chemical Works of Gedeon Richter's enterprise value is $5,931 Mil.
Chemical Works of Gedeon Richter's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $563 Mil. Therefore, Chemical Works of Gedeon Richter's EV-to-EBITDA for today is 10.54.
The historical rank and industry rank for Chemical Works of Gedeon Richter's EV-to-EBITDA or its related term are showing as below:
RGEDF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.91 Med: 9.97 Max: 25.5
Current: 10.79
During the past 13 years, the highest EV-to-EBITDA of Chemical Works of Gedeon Richter was 25.50. The lowest was 3.91. And the median was 9.97.
RGEDF's EV-to-EBITDA is ranked better than 59.3% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.96
vs RGEDF: 10.79
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Chemical Works of Gedeon Richter (OTCPK:RGEDF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Chemical Works of Gedeon Richter's PE Ratio (TTM) for today is calculated as:
Chemical Works of Gedeon Richter's share price for today is $36.9875.
Chemical Works of Gedeon Richter's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.061.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter EV-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Chemical Works of Gedeon Richter's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemical Works of Gedeon Richter EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chemical Works of Gedeon Richter's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Chemical Works of Gedeon Richter's EV-to-EBITDA falls into.
Chemical Works of Gedeon Richter's current Enterprise Value is $5,931 Mil.
Chemical Works of Gedeon Richter's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $563 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter (RGEDF) has a EV-to-EBITDA of 10.54 as of Jul. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Chemical Works of Gedeon Richter. This is near median its historical median of 9.97. Over the past decade, Chemical Works of Gedeon Richter's EV-to-EBITDA has ranged from 3.91 to 25.50. According to the industry distribution chart, Chemical Works of Gedeon Richter ranks #302 out of 742 companies in the Drug Manufacturers industry, placing it in the top 40.7%.
Is Chemical Works of Gedeon Richter's EV-to-EBITDA too high?
Chemical Works of Gedeon Richter's current EV-to-EBITDA of 10.54 is near median its 10-year median of 9.97. Over the past 10 years, this metric has ranged from a low of 3.91 to a high of 25.50. The Drug Manufacturers industry median EV-to-EBITDA is 12.96. Chemical Works of Gedeon Richter's value of 10.54 is 18.7% below this industry median. Based on the distribution chart, Chemical Works of Gedeon Richter ranks #302 out of 742 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Chemical Works of Gedeon Richter has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chemical Works of Gedeon Richter's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chemical Works of Gedeon Richter ranks #302 out of 742 companies for EV-to-EBITDA. This puts Chemical Works of Gedeon Richter in the upper half of its industry. The industry median EV-to-EBITDA is 12.96. Chemical Works of Gedeon Richter's value of 10.54 is 18.7% below this benchmark. Historically, Chemical Works of Gedeon Richter's own EV-to-EBITDA has ranged from 3.91 to 25.50 over the past decade. While the company's 10-year median is 9.97 vs. the industry median of 12.96, Chemical Works of Gedeon Richter has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.96, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemical Works of Gedeon Richter's current EV-to-EBITDA of 10.54 is 18.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Chemical Works of Gedeon Richter. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemical Works of Gedeon Richter's current EV-to-EBITDA is 10.54, which is near median its own 10-year median of 9.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemical Works of Gedeon Richter stock overvalued right now?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter (RGEDF) is currently considered Fairly Valued. The stock's GF Value™ is $35.16, compared to a current price of $36.99 — trading 5.2% above its estimated fair value. The current EV-to-EBITDA is 10.54, which is near median its 10-year median of 9.97 and 18.7% below the Drug Manufacturers industry median of 12.96. Chemical Works of Gedeon Richter's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Chemical Works of Gedeon Richter (RGEDF), the current EV-to-EBITDA is 10.54 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemical Works of Gedeon Richter (RGEDF) Overvalued in 2026?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter stock appears to be overvalued.
The current stock price of $36.99 is trading 5.2% above its estimated GF Value™ of $35.16.
GuruFocus considers Chemical Works of Gedeon Richter to be Fairly Valued.
Key valuation signals for RGEDF:
EV-to-EBITDA: 10.54 (near median its 10-year median of 9.97)
GF Value™: $35.16 vs. price of $36.99 (5.2% above fair value)
Industry Position: 18.7% below the Drug Manufacturers median (#302 of 742)
No single metric tells the full story. See the RGEDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemical Works of Gedeon Richter Business Description
Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women's Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.
94GF Score
Get the complete analysis for RGEDF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEDF has been successfully added to your 
